[Pubmed] Rapid Onset of Clinical Response to Eculizumab in a Single-Center Cohort of Older Patients with Refractory Gene

[RSS-Bot]

NeuroSci. 2026 Jul 24;7(4):85. doi: 10.3390/neurosci7040085.

ABSTRACT

BACKGROUND: Current treatments for myasthenia gravis (MG), while improving outcomes, are often associated with adverse effects, and a proportion of patients remain refractory to standard therapies. Eculizumab, a humanized monoclonal antibody targeting complement protein C5, is approved for refractory anti-acetylcholine receptor antibody-positive generalized MG (AChR-Ab+ gMG). Aim of the present study is to explore the rapidity of onset of eculizumab efficacy in a single-center cohort of MG patients.

METHODS: This retrospective, observational, single-center study evaluated the real-world effectiveness and rapidity of response to eculizumab in patients with AChR-Ab+ gMG. Patients received eculizumab according to the approved regimen and were assessed at baseline (T0), 5 weeks (T1), and 3 months (T2) using the Myasthenia Gravis Activities of Daily Living (MG-ADL) score, Quantitative Myasthenia Gravis (QMG) score, and Myasthenia Gravis Foundation of America (MGFA) classification.

RESULTS: Eight patients were eligible for the study with a mean age of 73.1 years. A rapid clinical improvement was observed after treatment initiation. Mean MG-ADL scores decreased from 8.38 at T0 to 2.13 at T1 (p < 0.001; Cohen's d = 2.075), while QMG scores declined from 13.75 to 5.63 (p = 0.001; Cohen's d = 1.824). Improvements were maintained at T2. Mean percentage reductions from T0 to T1 were 73.5% for MG-ADL and 60.6% for QMG. Eculizumab was well tolerated.

CONCLUSIONS: These real-world findings confirm a rapid and clinically meaningful response to eculizumab in elderly patients with refractory gMG. These findings highlight its potential role in achieving early symptom control and reducing disease burden in this clinically vulnerable population.

PMID:42646495 | PMC:PMC13516849 | DOI:10.3390/neurosci7040085


Source: https://pubmed.ncbi.nlm.nih.gov/4264649 ... 8&v=2.20.1